<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993677</url>
  </required_header>
  <id_info>
    <org_study_id>SGNS40-002</org_study_id>
    <secondary_id>KEYNOTE-C86</secondary_id>
    <nct_id>NCT04993677</nct_id>
  </id_info>
  <brief_title>A Study of SEA-CD40 Given With Other Drugs in Cancers</brief_title>
  <official_title>An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with&#xD;
      other cancer drugs to treat some types of cancer. It will also study side effects from the&#xD;
      drug.&#xD;
&#xD;
      There are 2 parts in this trial. In one part, participants have melanoma that has come back&#xD;
      after treatment or can't be removed by surgery. Participants in this part will get SEA-CD40&#xD;
      and pembrolizumab. In the other part, participants have non-small cell lung cancer (NSCLC)&#xD;
      that has spread through their body. These participants will get SEA-CD40, pembrolizumab,&#xD;
      carboplatin, and pemetrexed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Objective Response Rate (ORR)</measure>
    <time_frame>Duration of treatment, approximately 2 years</time_frame>
    <description>The proportion of subjects who achieve a confirmed complete response (CR) or partial (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>From start of treatment to 30-37 days after last dose, approximately 2 years</time_frame>
    <description>Any untoward medical occurrence in a subject or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>From start of treatment to 30-37 days after last dose, approximately 2 years</time_frame>
    <description>To be summarized using descriptive statistics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose alterations</measure>
    <time_frame>Duration of treatment, approximately 2 years</time_frame>
    <description>To be summarized using descriptive statistics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) per investigator assessment</measure>
    <time_frame>From start of treatment until completion of response assessment, approximately 4 years</time_frame>
    <description>The proportion of subjects who achieve a confirmed CR or PR according to RECIST v1.1 as assessed by the investigator or meet the stable disease (SD) criteria at least once after start of study treatment at a minimum interval of 5 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) per investigator assessment</measure>
    <time_frame>From start of treatment until completion of response assessment, approximately 4 years</time_frame>
    <description>The time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of progressive disease (PD) or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) per investigator assessment</measure>
    <time_frame>From start of treatment until completion of response assessment, approximately 4 years</time_frame>
    <description>The time from the start of study treatment to the first documentation of PD by RECIST v1.1 or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Duration of study, approximately 4 years</time_frame>
    <description>The time from the start of study treatment to date of death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Melanoma</condition>
  <condition>Carcinoma, Non-Small- Cell Lung</condition>
  <arm_group>
    <arm_group_label>Melanoma Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 + pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 + pembrolizumab + pemetrexed + carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEA-CD40</intervention_name>
    <description>Given into the vein (IV; intravenously); schedule is cohort-specific</description>
    <arm_group_label>Melanoma Arm</arm_group_label>
    <arm_group_label>NSCLC Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>Given by IV; schedule is cohort-specific.</description>
    <arm_group_label>Melanoma Arm</arm_group_label>
    <arm_group_label>NSCLC Arm</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>Given by IV on Day 1 of each 21-day cycle.</description>
    <arm_group_label>NSCLC Arm</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given by IV on Day 1 of Cycles 1-4. Each cycle will be 21 days long.</description>
    <arm_group_label>NSCLC Arm</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed unresectable malignancy defined as one of&#xD;
             the following:&#xD;
&#xD;
               -  Cohort 1: Relapsed and/or refractory metastatic melanoma&#xD;
&#xD;
                    -  Uveal/ocular melanoma is excluded&#xD;
&#xD;
                    -  Must have progressed on treatment with an anti-PD-(L)1 mAb. PD-(L)1&#xD;
                       treatment progression is defined as meeting all of the following criteria:&#xD;
&#xD;
          -  Has received at least 2 doses of an approved anti-PD-(L)1 mAb&#xD;
&#xD;
          -  Has demonstrated disease progression after PD-(L)1 as defined by RECIST v1.1.&#xD;
&#xD;
          -  Progressive disease has been documented within 12 weeks from the last dose of anti-&#xD;
             PD-(L)1 mAb&#xD;
&#xD;
          -  Last dose of anti-PD-(L)1 must have been within 90 days prior to enrollment&#xD;
&#xD;
               -  Cohort 2: Metastatic uveal melanoma&#xD;
&#xD;
                    -  Must not have received prior treatment for advanced or metastatic disease&#xD;
                       except for prior adjuvant/neoadjuvant immunotherapy&#xD;
&#xD;
                    -  No prior regional, liver-directed therapy&#xD;
&#xD;
               -  Cohort 3: Metastatic PD-(L)1-na√Øve melanoma&#xD;
&#xD;
                    -  Uveal/ocular melanoma is excluded&#xD;
&#xD;
                    -  Must not have received prior treatment for advanced or metastatic disease&#xD;
                       except for prior adjuvant/neoadjuvant immunotherapy.&#xD;
&#xD;
                    -  Participants with BRAF mutation, prior BRAF/MEK targeted therapy is allowed&#xD;
                       if completed 4 weeks prior to first dose of study treatment.&#xD;
&#xD;
               -  Cohorts 4 and 5: Non-squamous NSCLC&#xD;
&#xD;
                    -  Participants must have stage IV disease per AJCC 8th edition&#xD;
&#xD;
                    -  No known driver mutations/alterations mutation for which targeted therapy is&#xD;
                       available&#xD;
&#xD;
                    -  Must have non-squamous histology.&#xD;
&#xD;
                    -  No prior therapy for metastatic disease&#xD;
&#xD;
                    -  No prior treatment with anti-PD-(L)1 or PD-L2 agent or an antibody targeting&#xD;
                       other immuno-regulatory receptors or mechanisms&#xD;
&#xD;
          -  Able to provide archival tumor tissue from locations not radiated prior to biopsy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1&#xD;
&#xD;
          -  Measurable disease per RECIST v1.1 at baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of another malignancy within 3 years of first dose of study drug&#xD;
&#xD;
          -  Active central nervous system (CNS) metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          -  Previous exposure to CD40-targeted therapy&#xD;
&#xD;
          -  Currently on chronic systemic steroids in excess of physiologic replacement&#xD;
&#xD;
          -  Has had an allogeneic tissue/solid organ transplant.&#xD;
&#xD;
          -  History of autoimmune disease that has required systemic treatment in the past 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Hayman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seagen Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allie Pittman</last_name>
      <email>apittman@hogonc.com</email>
    </contact>
    <investigator>
      <last_name>J. Thaddeus Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angeles Clinic and Research Institute, The</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saba Mukarram</last_name>
      <email>smukarram@theangelesclinic.org</email>
    </contact>
    <investigator>
      <last_name>Omid Hamid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - North Region</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy White</last_name>
      <email>wwhite@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynne Schroeder</last_name>
      <email>lynne.schroeder@allina.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Amatruda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Ann Wiggs</last_name>
      <email>carolann.wiggs@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research, LLC</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nashat Gabrail</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kierstyn Hayden</last_name>
      <email>HAYDENK2@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology-Nashville/Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Rector</last_name>
      <email>Sharon.Rector@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Vardeleon</last_name>
      <email>agvardeleon@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Sapna Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed melanoma</keyword>
  <keyword>Refractory melanoma</keyword>
  <keyword>Metastatic uveal melanoma</keyword>
  <keyword>Metastatic PD-(L)1-na√Øve melanoma</keyword>
  <keyword>Non-squamous NSCLC</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

